Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108
Palisade Bio (NASDAQ:PALI) has released a Virtual Investor KOL Connect segment featuring Dr. Brian G. Feagan, a leading expert in Fibrostenotic Crohn's Disease (FSCD) and Inflammatory Bowel Diseases (IBD). The segment focuses on the company's lead candidate PALI-2108 and its potential impact on FSCD treatment.
Dr. Feagan, a Professor of Medicine at Western University and Senior Scientific Director at Alimentiv, Inc., discussed the significant unmet need in FSCD treatment and highlighted PALI-2108's novel approach. The drug candidate is designed to provide localized treatment that reduces side effects while maintaining anti-inflammatory and anti-fibrotic activity.
Palisade Bio (NASDAQ:PALI) ha pubblicato un segmento Virtual Investor KOL Connect con Dr. Brian G. Feagan, esperto di punta nella Malattia di Crohn fibrostenotica (FSCD) e nelle Malattie Infiammatorie Intestinali (IBD). Il segmento è incentrato sul candidato principale dell'azienda, PALI-2108, e sul suo potenziale impatto nel trattamento della FSCD.
Il Dr. Feagan, Professore di Medicina alla Western University e Senior Scientific Director presso Alimentiv, Inc., ha sottolineato l'importante bisogno insoddisfatto nel trattamento della FSCD e ha illustrato l'approccio innovativo di PALI-2108. Il candidato farmaco è concepito per offrire un trattamento localizzato che riduca gli effetti collaterali mantenendo attività antiinfiammatoria e antifibrotica.
Palisade Bio (NASDAQ:PALI) ha lanzado un segmento Virtual Investor KOL Connect con Dr. Brian G. Feagan, experto destacado en Enfermedad de Crohn fibroesténica (FSCD) y Enfermedades Inflamatorias Intestinales (IBD). El segmento se centra en el candidato principal de la compañía, PALI-2108, y su posible impacto en el tratamiento de la FSCD.
El Dr. Feagan, Profesor de Medicina en Western University y Director Científico Senior en Alimentiv, Inc., habló sobre la considerable necesidad no cubierta en el tratamiento de la FSCD y destacó el enfoque novedoso de PALI-2108. El candidato está diseñado para proporcionar un tratamiento localizado que reduzca los efectos secundarios manteniendo actividad antiinflamatoria y antifibrótica.
Palisade Bio (NASDAQ:PALI)는 섬유협착성 크론병(FSCD) 및 염증성 장질환(IBD) 분야의 저명한 전문가인 Dr. Brian G. Feagan과의 Virtual Investor KOL Connect 영상을 공개했습니다. 해당 영상은 회사의 주요 후보물질인 PALI-2108와 FSCD 치료에 미칠 잠재적 영향을 다룹니다.
Western University 의학 교수이자 Alimentiv, Inc.의 수석 과학 이사인 Feagan 박사는 FSCD 치료에서 충족되지 않은 큰 수요를 언급하며 PALI-2108의 혁신적 접근법을 강조했습니다. 이 약물 후보는 부작용을 줄이면서 항염 및 항섬유화 활성을 유지하는 국소 치료를 제공하도록 설계되었습니다.
Palisade Bio (NASDAQ:PALI) a diffusé un segment Virtual Investor KOL Connect avec le Dr Brian G. Feagan, expert de premier plan sur la maladie de Crohn fibro-sténosante (FSCD) et les maladies inflammatoires de l'intestin (MII). Le segment se concentre sur le candidat principal de la société, PALI-2108, et son impact potentiel sur le traitement de la FSCD.
Le Dr Feagan, professeur de médecine à la Western University et directeur scientifique principal chez Alimentiv, Inc., a évoqué le besoin important non satisfait dans la prise en charge de la FSCD et a mis en avant l'approche novatrice de PALI-2108. Le candidat médicament est conçu pour offrir un traitement localisé réduisant les effets secondaires tout en conservant des activités anti-inflammatoires et anti-fibrotiques.
Palisade Bio (NASDAQ:PALI) hat ein Virtual Investor KOL Connect-Segment mit Dr. Brian G. Feagan veröffentlicht, einem führenden Experten für fibrostenotische Crohn-Krankheit (FSCD) und entzündliche Darmerkrankungen (IBD). Das Segment konzentriert sich auf den führenden Wirkstoffkandidaten des Unternehmens, PALI-2108, und dessen potenzielle Bedeutung für die FSCD-Therapie.
Dr. Feagan, Professor für Medizin an der Western University und Senior Scientific Director bei Alimentiv, Inc., sprach über den erheblichen ungedeckten Bedarf in der FSCD-Behandlung und hob den neuartigen Ansatz von PALI-2108 hervor. Der Kandidat ist darauf ausgelegt, eine lokalisierte Behandlung zu bieten, die Nebenwirkungen reduziert und gleichzeitig antiinflammatorische und antifibrotische Wirkungen erhält.
- Novel localized treatment approach potentially reducing side effects
- Lead candidate addresses both inflammation and fibrotic process in FSCD
- Endorsement from leading KOL in IBD research
- Early-stage development with no efficacy data presented
- No timeline provided for clinical development
– Moderated discussion with leading expert in Fibrostenotic Crohn's Disease (FSCD) and Inflammatory Bowel Diseases (IBD), Dr. Brian Feagan
– Segment provides further insight into the need for more effective treatment options for FSCD and how PALI-2108 may become a leader in the new frontier of IBD therapeutics
Carlsbad, CA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio,” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the release of a Virtual Investor KOL Connect segment featuring Dr. Brian G. Feagan, MD, FRCPC. Dr. Feagan is a Professor of Medicine, Epidemiology & Biostatistics at Western University, a practicing gastroenterologist at London Health Sciences Centre, and Senior Scientific Director at Alimentiv, Inc. He is a founding member of the Stenosis Therapy and Antifibrotic Research (STAR) Consortium, the founder of Robarts Clinical Trials (now Alimentiv), and globally recognized leaders in IBD clinical research. Dr. Feagan has directed more than 140 randomized controlled trials in Crohn’s disease and ulcerative colitis, developed widely used outcome measures including the Robarts Histopathology Index, and published extensively in the field. He is internationally recognized as a leading authority in FSCD and clinical trial design.
As part of the segment, Dr. Feagan discussed FSCD and the challenges with current approved therapies, highlighting the significant unmet need for more effective therapeutics that address both inflammation and the fibrotic process. He also provided his perspective on the novel approach of PALI-2108 and how it could potentially impact the overall treatment landscape. PALI-2108’s localized approach is designed to reduce class-associated side effects while preserving anti-inflammatory and anti-fibrotic activity.
The Virtual Investor KOL Connect segment featuring Palisade Bio is now available here.
For more information about PALI-2108 and the Company’s development plans, visit www.palisadebio.com.
About Palisade Bio
Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com
FAQ
What is PALI-2108 and how does it treat Fibrostenotic Crohn's Disease?
Who is Dr. Brian Feagan and why is his opinion on PALI-2108 significant?
What are the current challenges in treating Fibrostenotic Crohn's Disease?
Where can investors access Palisade Bio's KOL presentation about PALI-2108?
